



## A RARE ASSOCIATION OF NEUROMYELITIS OPTICA SPECTRUM DISORDER WITH SJOGREN'S SYNDROME: A CASE FROM WEST INDIA

**Dr. Sanjay Chaudhari**

Resident Doctor, Department Of Medicine, Smt. Nhl Municipal Medical College, Ellis Bridge, Ahmedabad.

**Dr. Dhanya Nair \***

Resident Doctor, Department Of Medicine, Smt. Nhl Municipal Medical College, Ellis Bridge, Ahmedabad. \*Corresponding Author

**Dr. Pavan Acharya**

Resident Doctor, Department of Medicine, Smt. NHL Municipal Medical College, Ellis bridge, Ahmedabad.

**ABSTRACT** Sjogren's syndrome(SS) is a chronic systemic disease characterized by inflammation and dysfunction of exocrine glands. A wide spectrum of neurologic manifestations ranging from asymptomatic brain lesions on MRI(3) to symptomatic brain lesions, meningitis, myelopathy, sensorimotor polyneuropathy and mononeuritis multiplex may accompany primary SS. NMO is relapsing neurological illness that has been sometimes reported in association with primary SS and SLE. Early diagnosis and treatment are critical in decreasing the possibility of irreversible severe neurological dysfunction.

**KEYWORDS :** Sjogren's Syndrome, Neuromyelitisoptica Spectrum Disorder (nmosd)

### INTRODUCTION:

Sjogren's syndrome(SS) is a chronic systemic disease characterized by inflammation and dysfunction of exocrine glands. Up to 65% of primary SS patients can experience extra glandular features including pulmonary, gastrointestinal, hematologic and neurologic disorders<sup>(1)</sup>. Symptomatic central nervous system involvement can be in form of myelopathy, optic neuritis, seizures, and cognitive dysfunction. NMO spectrum disorders (NMOSD) includes a wide range of neurologic conditions that express NMO antibody and shares features with NMO but do not meet the strict diagnostic criteria<sup>(2)</sup>. We report a rare case of SS complicated by neuromyelitisoptica spectrum disorder (NMOSD).

### CASE REPORT:

A 29-year-old female presented to us with complaints of fever with chills and loose stools. She was vitally stable on presentation. In the past, she had complain of diminished vision in left eye 10 years back which got resolved after taking treatment details of which is not known. 2 years down the line, she developed bilateral parotitis which was painful and associated with dryness of eye and mouth. For that she consulted rheumatologist and she was diagnosed to have Sjogren's syndrome on basis on clinical and laboratory findings (Table 2) and was put on immunosuppressants. After 3 years, she again started developing diminished vision in left eye. She was diagnosed to have optic neuritis in left eye on MRI and treated with corticosteroids. In current visit, her fever workup was found to be normal. Two days after admission, she started developing weakness in all four limbs with headache. The symptoms got worsened rapidly in several hours to the point that she had difficulty with ambulation. The patient's neurological examination was remarkable for hypertonias, decreased power (Lower limb 0/5; Upper limb 3/5), hyperreflexia along with sensory loss below umbilicus.

Gadolinium contrast enhanced magnetic resonance imaging (MRI) of the brain showed multiple confluent altered signal intensity lesions in subcortical and periventricular deep white matter of bilateral frontoparietal and occipital lobe, body of corpus callosum, left cerebral peduncle and left anterior pons (Fig 1&2) and spine screening showed few enhancing linear intramedullary lesions at C3-C4 level, D7 level and D10-D11 level (Fig 3). Her CSF routine examination was normal with raised IgG index and negative OCB (Table-1). Her serum NMO was sent and was found positive. So, diagnosis of NMOSD was made. Injection methylprednisolone 1 gm was given for 5 days followed by oral prednisone. She was discharged with improvement in limb weakness (Lower limb 2/5; Upper limb 5/5) on oral prednisone with instructions to taper to maintenance dose of 20 mg over 2 weeks.

**Table 1: Summary of NMOSD tests**


TEST	RESULT	NORMAL RANGE
IgG CSF	29.90 mg/dl	0-3.4 mg/dl
IgG Total Serum	1140 mg/dl	700-1600 mg/dl

CSF IgG Index	0.940	0.28-0.66
IgG Albumin Ratio	0.87	0.09-0.25
NMO1 (Aquaporin 4) Ab Serum	Positive	
MOG2 Ab Serum	Negative	
Oligoclonal Bands (CSF)	No Band	
Oligoclonal Bands (SERUM)	No Band	

1-Neuromyelitis Optics; 2-Myelin Oligodendrocyte Glycoprotein

**Table 2: Summary of autoimmune workup**

TEST	RESULT	NORMAL RANGE
ANA BY IF	1:100 NUCLEAR SPECKLED +4	
SS-A Ro	76 AU/ML	<1 AU/ML: Negative
SS-B La	80 AU/ML	<1 AU/ML: Negative
Scl-70	<1 AU/ML	<1 AU/ML: Negative
Ds-DNA Ab	<1 AU/ML	<1 AU/ML: Negative
Centromere	<1 AU/ML	<1 AU/ML: Negative
U1 Sn RNP	<1 AU/ML	<1 AU/ML: Negative
Ro-52	<1 AU/ML	<1 AU/ML: Negative
JO-1	<1 AU/ML	<1 AU/ML: Negative



**Fig 1: MRI Brain with multiple confluent altered signal intensity lesions**



**Fig 2: MRI Brain sagittal view**



**Fig 3: MRI T2 weighted sequence few enhancing linear intramedullary lesions at C3-C4 level, D7 level and D10-D11 level**

#### DISCUSSION:

Sjogren's syndrome (SS) is an autoimmune disease in which there is mononuclear infiltration of exocrine gland and salivary and lacrimal glands resulting in xerophthalmia and xerostomia, also known as sicca syndrome. Blood tests are usually positive for SSA/Ro or SSB/La antibodies. Rose Bengal test, Schirmer test, and saliva gland/lip biopsy can be done to support diagnosis.

Neurological involvement could be observed in approximately 20–25% of cases of SS. Neurological manifestation of SS involves central and peripheral nervous system. These range from asymptomatic brain lesions on MRI<sup>(3)</sup> to symptomatic brain lesions, meningitis, myelopathy, sensorimotor polyneuropathy and mononeuritis multiplex. Neurological involvement can be focal or multifocal central lesions to dementia and conditions that mimic MS such as neuromyelitis Optica (NMO) or NMOSD. NMO is relapsing neurological illness that has been sometimes reported in association with primary SS and SLE. NMO is characterized by recurrent episodes of optic neuritis and myelitis and most patients have antibody against NMO IgG/AQP4. NMO is characterized by two absolute criteria; (1) optic neuritis and (2) acute myelitis plus 2 of the 3 following supportive criteria: (1) brain MRI not meeting criteria of MS, (2) spinal cord MRI extending over three or more vertebral segments, and (3) NMO-IgG positive. There have been reports of SS complicated by NMOSD including long extended spinal cord lesion (LESCL). Min et al. and Estiasari et al. reported that the rates of central nervous system involvement in SS patients were with LESCL positive for the anti-AQP4 antibody in East Asia 42% and 18%, respectively<sup>(7,8)</sup>. However, SS complicated by NMO seems to be rare in non-East Asian regions. Kolfenbach et al. reviewed English literatures and found 21 cases of overlap SS and NMO with additional 5 more cases of their own<sup>(4)</sup>. Etiology of association between SS and NMO is still unclear. However, there is a retrospective blinded serological survey to support the evidence of coexisting NMO in NMOSD with positive NMO-IgG occurring with SS rather than as a complication of SS<sup>(5)</sup>. The first line treatment of acute attack of NMO is high dose intravenous methylprednisolone 1000mg daily for at least three to five days<sup>(6)</sup>. Plasmapheresis or cyclophosphamide may be considered if there is no clinical improvement with steroid therapy alone. Azathioprine, rituximab, mycophenolate mofetil, methotrexate, prednisone, or mitoxantrone can be used as maintenance therapy<sup>(6)</sup>.

#### CONCLUSION:

This is a case of NMOSD associated with connective tissue disease. The case supports the association between NMOSD and SS. Early diagnosis and treatment are critical in decreasing the possibility of irreversible severe neurological dysfunction. Awareness of the possibility of CNS disease is important because of the serious nature of CNS complications and because some are treatable with immunosuppressive medications. Our patient with SS who presented with NMOSD benefitted from early recognition and institution of appropriate therapy.

#### REFERENCES:

1. Ramos-Casala M, Anaya JM, Garcia-Carrasco M, Rosas J, Bove A, Claver G, Diaz LA, Herrero C, Font J: Cutaneous vasculitis in primary Sjogren's syndrome: classification and clinical significance of 52 patients. *Medicine* 2004, 83:96-100.
2. Jacob J, McKeon A, Nakashima I, Sato DK, Elson L, Fujihara K, de Seze J: Current concept of neuromyelitis optica and neuromyelitis optica spectrum disorders. *J Neurol Neurosurg Psychiatry* 2013, 84:922-930.
3. Pierot L, Sauve C, Leger JM, Martin N, Koeger AC, Wechsler B, Chiras J: Asymptomatic cerebral involvement in Sjogren's syndrome: MRI findings of 15 cases.

4. J. R. Kolfenbach, B. J. Horner, E. D. Ferucci, and S. G. West, "Neuromyelitis optica spectrum disorder in patients with connective tissue disease and myelitis," *Arthritis Care and Research*, vol. 63, no. 8, pp. 1203-1208, 2011.
5. S. J. Pittock, V. A. Lennon, J. de Seze et al., "Neuromyelitis optica and non-organ-specific autoimmunity," *Archives of Neurology*, vol. 65, no. 1, pp. 78-83, 2008.
6. D. J. Kimbrough, K. Fujihara, A. Jacob et al., "Treatment of neuromyelitis optica: review and recommendations," *Multiple Sclerosis and Related Disorders*, vol. 1 no. 4 pp. 180-187, 2012.
7. J. H. Min, H. J. Kim, B. J. Kim et al., "Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica," *Multiple Sclerosis*, vol. 15, no. 9, pp. 1069-1076, 2009.
8. R. Estiasari, T. Matsushita, K. Masaki et al., "Comparison of clinical, immunological and neuroimaging features between anti-aquaporin-4 antibody-positive and antibody-negative Sjogren's syndrome patients with central nervous system manifestations," *Multiple Sclerosis*, vol. 18, no. 6, pp. 807-816, 2012.